CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


COVID-19 RT-PCRWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug2791 Symptoms questionnare Wiki 0.58
drug422 Biosensor Wiki 0.58
drug2947 Traditional antirheumatic drugs Wiki 0.58
drug3327 lung ultrasound Wiki 0.58
drug2777 Survey administration Wiki 0.58
drug548 COVID-19 Serology Wiki 0.41

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D001171 Arthritis, Juvenile NIH 0.58
D001168 Arthritis NIH 0.32
D001172 Arthritis, Rheumatoid NIH 0.20
D001008 Anxiety Disorders NIH 0.09

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001369 Arthritis HPO 0.32
HP:0001370 Rheumatoid arthritis HPO 0.20

There are 3 clinical trials

Clinical Trials


1 Evaluation of the Immune Response in Symptomatic and Asymptomatic Patients' Diagnosed Witih COVID-19

The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.

NCT04348422 COVID-19 Diagnostic Test: COVID-19 RT-PCR Diagnostic Test: COVID-19 Serology Other: Symptoms questionnare

Primary Outcomes

Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection

Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA)

Time: 100 days

Description: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection

Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)

Time: 100 days

Secondary Outcomes

Description: the mean time patients devleoped IgM

Measure: Time to IgM

Time: Evaluated within a 100 days followup

Description: the mean time patients devleoped IgG

Measure: Time to IgG

Time: Evaluated within a 100 days followup

Description: the mean time patients devleoped IgG

Measure: Time to IgA

Time: Evaluated within a 100 days followup

Description: Cohen's kappa coefficient calculated between the different serology kits used for evaluation

Measure: Serology kits inter-observer agreement

Time: Evaluated within a 100 days followup

2 Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept

The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.

NCT04367142 Sars-CoV2 Diagnostic Test: COVID-19 RT-PCR Diagnostic Test: Biosensor

Primary Outcomes

Measure: Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team

Time: Baseline (at admission)

Secondary Outcomes

Measure: Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission

Time: Baseline (at admission)

3 Use of Lung Ultrasound in Patients Suspected of COVID-19 Infection in the Emergency Room

Covid-19 (English acronym meaning coronavirus disease 2019) is an emerging infectious disease caused by a strain of coronavirus called SARS-CoV-2. The current pandemic has resulted in a significant number of admissions in the emergency room (ER) due to suspicion of COVID-19 infection. Use of lung ultrasound is standard practice to diagnose acute respiratory failure in ER. Recently, typical lung ultrasonographic characteristics of COVID-19 disease has been described. During the COVID-19 pandemic, the use of this tool could be of interest in order to allow an early, simple and reliable triage in patients with suspected COVID-19 infection admitted in ER. In addition, the visualization of early signs in specific areas could be a predictive marker of the severity of the disease. The objective of this project will be to study the association between the signs on lung ultrasound and the result of RT-PCR in patients with suspected COVID-19 infection in the ER.

NCT04368338 Covid-19 Lung Ultrasound Respiratory Complication Diagnostic Test: COVID-19 RT-PCR Procedure: lung ultrasound

Primary Outcomes

Description: Polymerase chain reaction tests after reverse transcription for the detection of covid-19 viral RNA will be done as biological test.

Measure: Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease

Time: 6 months


No related HPO nodes (Using clinical trials)